High­land who? Biotech gets a $200M war chest to crack the US AD­HD mar­ket

At sev­er­al points last year, Toron­to-based High­land Ther­a­peu­tics spot­light­ed da­ta from a pair of piv­otal Phase III stud­ies of Ben­jor­na (HLD-200) which they say pro­vid­ed clear ev­i­dence that a night­ly dose of the drug upped the per­for­mance of kids with AD­HD from morn­ing through night. Now, star­ing down a Ju­ly 30 PDU­FA date with the FDA, the low-pro­file biotech has raised $200 mil­lion to fund the com­mer­cial ramp-up, con­fi­dent that they’re now a few short steps from shak­ing up a ma­jor mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER